Risk factors for arterial thrombosis in antiphospholipid syndrome.

No abstract is available for this paper.

• Publication year

  2014

• Venue

  Thrombosis Research

• Publication date

  2014-02-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/j.thromres.2013.11.012PMID 24321419
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• International consensus guidelines on anticardiolipin and anti-β2-glycoprotein I testing: report from the 13th International Congress on Antiphospholipid Antibodies.

  2012cited by this paper
• Morbidity, Mortality, and Organ Damage in Patients with Antiphospholipid Syndrome

  2012cited by this paper
• Factors and comorbidities associated with first neuropsychiatric event in systemic lupus erythematosus: does a risk profile exist? A large multicentre retrospective cross-sectional study on 959 Italian patients.

  2012cited by this paper
• Antiphospholipid antibodies and the brain: A consensus report

  2011cited by this paper
• Platelet adhesion and activation mechanisms in arterial thrombosis and ischaemic stroke

  2011cited by this paper
• Risk factors for a first thrombotic event in antiphospholipid antibody carriers: a prospective multicentre follow-up study

  2011cited by this paper
• Lupus anticoagulant: performance of the tests as recommended by the latest ISTH guidelines

  2011cited by this paper
• Incidence of a first thromboembolic event in asymptomatic carriers of high-risk antiphospholipid antibody profile: a multicenter prospective study.

  2011cited by this paper
• Determinants of Risk for Venous and Arterial Thrombosis in Primary Antiphospholipid Syndrome and in Antiphospholipid Syndrome with Systemic Lupus Erythematosus

  2009cited by this paper
• Morbidity and mortality in the antiphospholipid syndrome during a 10-year period: a multicentre prospective study of 1000 patients

  2009cited by this paper
• Antiphospholipid antibodies and risk of myocardial infarction and ischaemic stroke in young women in the RATIO study: a case-control study.

  2009cited by this paper
• Update of the guidelines for lupus anticoagulant detection

  2009cited by this paper
• The Euro-Phospholipid project: epidemiology of the antiphospholipid syndrome in Europe

  2009cited by this paper
• Risk factors for thrombosis and primary thrombosis prevention in patients with systemic lupus erythematosus with or without antiphospholipid antibodies.

  2008cited by this paper
• Risk factors for a first thrombotic event in antiphospholipid antibody carriers. A multicentre, retrospective follow-up study

  2008cited by this paper
• Morbidity and mortality in the antiphospholipid syndrome during a 5-year period: a multicentre prospective study of 1000 patients

  2008cited by this paper
• Double heterozygosity polymorphisms for platelet glycoproteins Ia/IIa and IIb/IIIa increases arterial thrombosis and arteriosclerosis in patients with the antiphospholipid syndrome or with systemic lupus erythematosus

  2007cited by this paper
• The Pl(A1/A2) polymorphism of glycoprotein IIIa and cerebrovascular events in hypertension: increased risk of ischemic stroke in high-risk patients.

  2007cited by this paper
• Anti‐beta 2 glycoprotein I antibodies and the risk of myocardial infarction in young premenopausal women

  2007cited by this paper
• Transiently positive anticardiolipin antibodies and risk of thrombosis in patients with systemic lupus erythematosus

  2007cited by this paper
• Revised classification criteria for antiphospholipid syndrome and the thrombotic risk in patients with autoimmune diseases

  2007cited by this paper
• The PlA1/A2 polymorphism of glycoprotein IIIa and cerebrovascular events in hypertension: increased risk of ischemic stroke in high-risk patients

  2007cited by this paper
• Genetic polymorphisms of platelet glycoprotein Ia and the risk for premature myocardial infarction: effects on the release of sCD40L during the acute phase of premature myocardial infarction.

  2006cited by this paper
• Valine/Leucine247 polymorphism of β2-glycoprotein I in patients with antiphospholipid syndrome: lack of association with anti-β2-glycoprotein I antibodies

  2006cited by this paper
• Anti-beta2-glycoprotein I: prevalence, clinical correlations, and importance of persistent positivity in patients with antiphospholipid syndrome and systemic lupus erythematosus.

  2006cited by this paper
• International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS)

  2006cited by this paper
• Thrombotic Risk Factors In Primary Antiphospholipid Syndrome: A 5-Year Prospective Study

  2005cited by this paper
• Dermatologic manifestations of the antiphospholipid syndrome: two hundred consecutive cases.

  2005cited by this paper
• Pathophysiology of the antiphospholipid syndrome

  2005cited by this paper
• Anticardiolipin Antibodies and Risk of Ischemic Stroke and Transient Ischemic Attack: The Framingham Cohort and Offspring Study

  2004cited by this paper
• Lupus anticoagulants are stronger risk factors for thrombosis than anticardiolipin antibodies in the antiphospholipid syndrome: a systematic review of the literature.

  2003cited by this paper
• Anti-beta 2-glycoprotein I, antiprothrombin antibodies, and the risk of thrombosis in the antiphospholipid syndrome.

  2003cited by this paper
• A cross-sectional study of clinical thrombotic risk factors and preventive treatments in antiphospholipid syndrome.

  2002cited by this paper
• Antiphospholipid syndrome: clinical and immunologic manifestations and patterns of disease expression in a cohort of 1,000 patients.

  2002cited by this paper
• Risk factors associated with thrombosis in patients with antiphospholipid antibodies.

  2001cited by this paper
• The Elements of Statistical Learning: Data Mining, Inference, and Prediction

  2001cited by this paper
• &bgr;2-Glycoprotein 1–Dependent Anticardiolipin Antibodies and Risk of Ischemic Stroke and Myocardial Infarction: The Honolulu Heart Program

  2001cited by this paper
• Cerebrovascular ischemic events with high positive anticardiolipin antibodies.

  1998cited by this paper
• Anticardiolipin, anti-beta(2)-glycoprotein I, antiprothrombin antibodies, and lupus anticoagulant in patients with systemic lupus erythematosus with a history of thrombosis.

  1997cited by this paper
• Thrombosis and systemic lupus erythematosus: the Hopkins Lupus Cohort perspective.

  1996cited by this paper
• Evaluation of the anti-cardiolipin antibody test: report of an international workshop held 4 April 1986.

  1987cited by this paper

• Thrombosis in systemic lupus erythematous patients: analysis of COMOSLE-Egypt study population

  2025cites this paper
• Identification of Phenotypes in Thrombotic Primary Antiphospholipid Syndrome Using Cluster Analysis: A step Towards Personalized Medicine.

  2025cites this paper
• Risk factors for cerebral infarction and cerebrovascular stenosis in antiphospholipid antibody-positive patients: A retrospective single-center study with propensity score matching analysis

  2024cites this paper
• Pediatric antiphospholipid syndrome: is it the same as an adult?

  2024influential citation
• Neurovascular Issues in Antiphospholipid Syndrome: Arterial Vasculopathy from Small to Large Vessels in a Neuroradiological Perspective

  2024cites this paper
• Management of Cardiovascular Complications in Antiphospholipid Syndrome: A Narrative Review with a Focus on Older Adults

  2024cites this paper
• Phenotypes in antiphospholipid syndrome: A hierarchical cluster analysis based on two independent databases.

  2024cites this paper
• Patients with antiphospholipid syndrome and a first venous or arterial thrombotic event: clinical characteristics, antibody profiles and estimate of the risk of recurrence

  2024cites this paper
• Risk Factors for Antiphospholipid Antibodies and Antiphospholipid Syndrome

  2024influential citation
• Accelerated atherosclerosis and management of cardiovascular risk in autoimmune rheumatic diseases: an updated review.

  2023cites this paper
• Multiple intrathoracic thrombosis detected on ct scan in patient with antiphospholipid antibody syndrome: case report

  2023cites this paper
• Effect of smoking on thrombotic antiphospholipid syndrome: a 10-year prospective cohort study.

  2023cites this paper
• Severe cutaneous necrosis in antiphospholipid syndrome

  2023cites this paper
• Application of EULAR and European Society of Cardiology recommendations with regard to blood pressure and lipid management in antiphospholipid syndrome

  2023cites this paper
• Risk of subclinical atherosclerosis in patients with antiphospholipid syndrome and subjects with antiphospholipid antibody positivity: A systematic review and meta-analysis.

  2023cites this paper
• Mechanisms of immunothrombosis and vasculopathy in antiphospholipid syndrome

  2022cites this paper
• Antiphospholipid Syndrome-Related Pulmonary Embolism: Clinical Characteristics and Early Recognition

  2022cites this paper
• Cardiovascular disease risk in antiphospholipid syndrome: Thrombo-inflammation and atherothrombosis.

  2022cites this paper
• Additional risk factors associated with thrombosis and pregnancy morbidity in a unique cohort of antiphospholipid antibody-positive patients

  2022cites this paper
• Thrombocytopenia in a cohort of primary and secondary antiphospholipid syndrome patients: Relation to clinical, laboratory manifestations and damage index

  2022cites this paper
• Cardiac and vascular features of arterial and venous primary antiphospholipid syndrome. The multicenter ATHERO-APS study.

  2021cites this paper
• VWF, Platelets and the Antiphospholipid Syndrome

  2021cites this paper
• Clinical characteristics and prognosis of patients with isolated thrombotic vs. obstetric antiphospholipid syndrome: a prospective cohort study

  2021cites this paper
• A systematic review of the association between anti-β-2 glycoprotein I antibodies and APS manifestations

  2021cites this paper
• Platelet Dysregulation in the Pathobiology of COVID-19

  2021cites this paper
• Cardiovascular risk management in antiphospholipid syndrome: trends over time and comparison with rheumatoid arthritis and diabetes mellitus

  2021cites this paper
• An Update on Antiphospholipid Syndrome

  2021cites this paper
• Thrombotic microangiopathy in primary antiphospholipid syndrome is linked to stroke and less deep venous thrombosis.

  2021cites this paper
• Infarto agudo de miocardio como manifestación inicial de síndrome antifosfolípido primario: Reporte de Caso

  2020cites this paper
• Antiplatelet and anticoagulant agents for secondary prevention of stroke and other thromboembolic events in people with antiphospholipid syndrome.

  2020cites this paper
• IgG Anti-high-Density Lipoproteins Antibodies Discriminate Between Arterial and Venous Events in Thrombotic Antiphospholipid Syndrome Patients

  2019cites this paper
• Management of Antiphospholipid Syndrome in Patients with Systemic Lupus Erythematosus

  2019cites this paper
• Disease activity and thromboembolic events in women with systemic lupus erythematosus with and without anti-phospholipid syndrome: users of the 52-mg levonorgestrel-releasing intrauterine system

  2019cites this paper
• Rivaroxaban Versus Vitamin K Antagonist in Antiphospholipid Syndrome

  2019cites this paper
• Impact des anticorps antiphospholipides sur l’hypertension artérielle et le devenir rénal dans la néphropathie lupique classe III/IV

  2018cites this paper
• Identifying Additional Risk Factors for Thrombosis and Pregnancy Morbidities Among Antiphospholipid Antibodies Carriers

  2018cites this paper
• Primary Thrombosis Prophylaxis in Persistently Antiphospholipid Antibody-Positive Individuals: Where Do We Stand in 2018?

  2018influential citation
• Antiplatelet and anticoagulant agents for secondary prevention of stroke and other thromboembolic events in people with antiphospholipid syndrome.

  2017cites this paper
• Recurrent Pregnancy Loss and Cardiovascular Disease Mortality in Japanese Women: A Population-Based, Prospective Cohort Study.

  2017cites this paper
• Definition and Epidemiology of Antiphospholipid Syndrome

  2017cites this paper
• Prognosis in Antiphospholipid Syndrome

  2017cites this paper
• Primary Prophylaxis in Patients With Positive Antiphospholipid Antibodies

  2017cites this paper
• Diagnosing antiphospholipid syndrome: 'extra-criteria' manifestations and technical advances

  2017cites this paper
• Thrombin activatable fibrinolysis inhibitor (TAFI) - A possible link between coagulation and complement activation in the antiphospholipid syndrome (APS).

  2017cites this paper
• Surgical Interventions for Organ and Limb Ischemia Associated With Primary and Secondary Antiphospholipid Antibody Syndrome With Arterial Involvement

  2017cites this paper
• Antiphospholipid syndrome.

  2016cites this paper
• Prevention of thrombosis in antiphospholipid syndrome.

  2016cites this paper
• Prevention of Recurrent Thrombosis in Antiphospholipid Syndrome: Different from the General Population?

  2016cites this paper
• IgG/IgM antiphospholipid antibodies present in the classification criteria for the antiphospholipid syndrome: a critical review of their association with thrombosis

  2016cites this paper
• Antiphospholipid Antibody Carriers

  2015cites this paper
• Acquired neurocutaneous disorders.

  2015cites this paper
• Recurrent thrombosis in antiphospholipid syndrome may be associated with cardiovascular risk factors and inflammatory response.

  2015cites this paper
• Secondary Raynaud’s Phenomenon

  2015cites this paper
• Neurological antiphospholipid syndrome: Clinical, neuroimaging, and pathological characteristics.

  2014cites this paper